Ozempic Drug Classification
Ozempic (semaglutide) is a GLP-1 receptor agonist (glucagon-like peptide-1 receptor agonist), a class of medications that selectively binds to and activates GLP-1 receptors to regulate blood glucose and promote weight loss. 1
Mechanism of Action
Semaglutide functions as a GLP-1 analog with 94% sequence homology to human GLP-1, acting through several key mechanisms 1:
- Glucose-dependent insulin secretion: Stimulates insulin release from pancreatic beta cells only when blood glucose is elevated, minimizing hypoglycemia risk 1
- Glucagon suppression: Reduces glucagon secretion in a glucose-dependent manner, decreasing hepatic glucose production 1
- Delayed gastric emptying: Slows the rate at which nutrients enter circulation in the early postprandial phase 1
- Central appetite suppression: Acts on hypothalamic receptors to reduce food intake and promote satiety 2
Pharmacological Properties
The extended half-life of approximately 1 week allows for once-weekly subcutaneous administration 1, 3. This protraction results from albumin binding facilitated by a C18 fatty di-acid modification at position 26, along with stabilization against DPP-4 enzyme degradation through modification at position 8 1.
Clinical Classification Context
Within the broader antihyperglycemic medication landscape, GLP-1 receptor agonists like semaglutide represent a distinct drug class separate from 4, 5:
- SGLT2 inhibitors (empagliflozin, canagliflozin, ertugliflozin)
- Dual GIP/GLP-1 receptor agonists (tirzepatide) - though related, this represents a separate class with dual receptor activation 2, 6
- DPP-4 inhibitors - which should not be combined with GLP-1 receptor agonists 2
The American Diabetes Association and FDA recognize semaglutide specifically as a GLP-1 receptor agonist indicated for improving glycemic control in type 2 diabetes and, at higher doses (2.4mg weekly), for chronic weight management 5, 2.